Searchable abstracts of presentations at key conferences in endocrinology

ea0016p121 | Clinical cases | ECE2008

Primary squamous cell carcinoma of the thyroid

Mussig Karsten , Dahm Julia , Koitschev Assen , Horger Marius , Muller Mark , Bares Roland , Wehrmann Manfred

Background: Primary squamous cell carcinomas of the thyroid are uncommon entities with less than 100 cases described in the literature.Case report: We report on the imaging findings in a rare case of primary squamous cell carcinoma of the thyroid that was found to be the primary tumour of humerus and cervical lymph node metastases. Other sources of squamous cell cancer were ruled out by a careful search, including whole body computed tomography (CT), pos...

ea0044ep97 | (1) | SFEBES2016

Graves’ disease with fluctuating thyroid status and hypothyroidism with positive anti-TSH receptor antibody levels – distinctive autoimmune side-effects following alemtuzumab therapy for multiple sclerosis

Pariani Nadia , Willis Mark , Muller Ilaria , Healy Sarah , Nasser Taha , Jones Joanne , Chatterjee V. Krishna K. , Dayan Colin , Robertson Neil , Coles Alasdair , Moran Carla

Alemtuzumab, a highly effective, newly-licensed, treatment for multiple sclerosis (MS), is notably associated with GravesÂ’ disease (GD), which reportedly has an indolent course.Methods: Case record review of patients who developed thyroid dysfunction (TD) after alemtuzumab treatment in Cambridge & Cardiff, to determine type, frequency and course of TD.Results: 41.8% (104/249; 81F, 23M) of alemtuzumab-treated patients devel...